AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34174778 — intervention group
Group type: COMPARATOR
Intervention: do-nothing arm
Number of subjects: 15163
Study 34174778 — intervention group
Group type: COMPARATOR
Intervention: attention placebo control (APC) arm
Number of subjects: 15163
Study 32618251 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA (Mass Drug Administration)
Number of subjects: 300000
Study 32618251 — intervention group
Group type: EXPERIMENTAL
Intervention: fMDA (Focal Mass Drug Administration)
Number of subjects: 300000
Study 32618251 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA
Number of subjects: 300000
Study 32618251 — intervention group
Group type: EXPERIMENTAL
Intervention: fMDA
Number of subjects: 300000
Study 616689242 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 30
Study 616689242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortryptyline (TCA)
Number of subjects: 30
Study 34598638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone clouds with varying densities of tone pips
Number of subjects: 0
Study 34598638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse tone clouds
Number of subjects: 0
Study 34598638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone clouds of varying densities
Number of subjects: 0
Study 35833390 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle modification
Number of subjects: 14135
Study 35833390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14135
Study 34757312 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1.8g per day)
Number of subjects: 94
Study 34757312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 33092591 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol 62.5/25 μg
Number of subjects: 2418
Study 33092591 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium 62.5 μg
Number of subjects: 2418
Study 33092591 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 2418
Study 35838363 — intervention group
Group type: EXPERIMENTAL
Intervention: rhMG53 protein (2 mg/kg, intravenous)
Number of subjects: 5
Study 35838363 — intervention group
Group type: COMPARATOR
Intervention: Normal saline control
Number of subjects: 5
Study 33930124 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone 400 mg twice daily plus oral dydrogesterone 10 mg twice daily
Number of subjects: 1364
Study 33930124 — intervention group
Group type: COMPARATOR
Intervention: Vaginal micronized progesterone 400 mg twice daily
Number of subjects: 1364
Study 35470385 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative stem cell transplant (SCT)
Number of subjects: 0
Study 35470385 — intervention group
Group type: COMPARATOR
Intervention: No consolidative stem cell transplant (SCT)
Number of subjects: 0
Study 34469696 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 0
Study 34469696 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched water (control)
Number of subjects: 0
Study 32169111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation plus treatment as usual (TAU)
Number of subjects: 50
Study 32169111 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo) plus TAU
Number of subjects: 50
Study 32169111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation plus TAU
Number of subjects: 50
Study 34228379 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation study arm
Number of subjects: 24837
Study 34228379 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 24837
Study 34228379 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of sons
Number of subjects: 24837
Study 34228379 — intervention group
Group type: COMPARATOR
Intervention: Maternal nutritional status and diet
Number of subjects: 24837
Study 33706569 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 30 minutes/day, five times/week over six weeks
Number of subjects: 50
Study 33706569 — intervention group
Group type: COMPARATOR
Intervention: Sham IMT
Number of subjects: 50
Study 33706569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IMT and Sham IMT)
Number of subjects: 50
Study 32780949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release
Number of subjects: 438
Study 32780949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 438
Study 32780949 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release
Number of subjects: 438
Study 32780949 — intervention group
Group type: COMPARATOR
Intervention: Control group (initial SSRI)
Number of subjects: 438
Study 35311432 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown flaxseed (BF)
Number of subjects: 30
Study 35311432 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden flaxseed (GF)
Number of subjects: 30
Study 35311432 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 34916722 — intervention group
Group type: COMPARATOR
Intervention: Same-day PEG-ASC regimen (5 mL sodium picosulfate in the evening and 1.5 L PEG-ASC on the day of colonoscopy)
Number of subjects: 153
Study 34916722 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose PEG-ASC regimen (1 L PEG-ASC before the day of colonoscopy and 1 L PEG-ASC on the day of colonoscopy)
Number of subjects: 153
Study 34916722 — intervention group
Group type: COMPARATOR
Intervention: Same-day PEG-ASC regimen
Number of subjects: 153
Study 34916722 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose PEG-ASC regimen
Number of subjects: 153
Study 35685566 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg once daily
Number of subjects: 1463
Study 35685566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1463
Study 32090517 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg plus IBT
Number of subjects: 282
Study 32090517 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus IBT
Number of subjects: 282
Study 33947442 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erector spinae plane block plus intravenous patient‐controlled analgesia with piritramide
Number of subjects: 90
Study 33947442 — intervention group
Group type: COMPARATOR
Intervention: Continuous thoracic epidural analgesia with a local anesthetic‐opioid infusate
Number of subjects: 90
Study 33619191 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinvasive pars plana vitrectomy (PPV)
Number of subjects: 272
Study 33619191 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 272
Study 32645164 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (Pitavastatin)
Number of subjects: 7770
Study 32645164 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐EPI and Modification of Diet in Renal Disease equations
Number of subjects: 7770
Study 35995357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined External Ventricular Drainage and Endoscope-Assisted Microsurgery (EAMS)
Number of subjects: 41
Study 35995357 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 33341937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide treatment in variant genotype group
Number of subjects: 117
Study 33341937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide treatment in intermediate group
Number of subjects: 117
Study 33341937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide treatment in wild-type genotype group
Number of subjects: 117
Study 33341937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide dosage in variant genotype group
Number of subjects: 117
Study 33341937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide dosage in wild-type genotype group
Number of subjects: 117
Study 33341937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide dosage in intermediate group
Number of subjects: 117
Study 32893098 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamics therapy
Number of subjects: 51
Study 32893098 — intervention group
Group type: COMPARATOR
Intervention: Home exercise therapy
Number of subjects: 51
Study 35551294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Number of subjects: 463
Study 35551294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 34039457 — intervention group
Group type: COMPARATOR
Intervention: Universal precautions (UP) - nitrile gloves and facemask with shield
Number of subjects: 27
Study 34039457 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial level C (PC) - rubber gloves and a passive air‐purifying respirator (APR)
Number of subjects: 27
Study 34039457 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete level C (CC) - passive APR with an anti‐chemical suit
Number of subjects: 27
Study 33239413 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PHMB 0.04%
Number of subjects: 90
Study 33239413 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PHMB 0.06%
Number of subjects: 90
Study 33239413 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PHMB 0.08%
Number of subjects: 90
Study 33239413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 90
Study 32757825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevention intervention
Number of subjects: 0
Study 32757825 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36177673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave therapy (LiESWT) at 0.25 mJ/mm2 and 3 pulses/second for a total of 3000 pulses over 8 weeks
Number of subjects: 30
Study 36177673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave therapy (LiESWT)
Number of subjects: 30
Study 34283220 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified uvulopalatopharyngoplasty with tonsillectomy (if tonsils present) combined with radiofrequency tongue ablation
Number of subjects: 43
Study 34283220 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 43
Study 32901950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute cryoballoon application (short)
Number of subjects: 222
Study 32901950 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes cryoballoon application (medium)
Number of subjects: 222
Study 32901950 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minutes cryoballoon application (long)
Number of subjects: 222
Study 32901950 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 222
Study 32901950 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 222
Study 32901950 — intervention group
Group type: EXPERIMENTAL
Intervention: Left superior PV
Number of subjects: 222
Study 32901950 — intervention group
Group type: EXPERIMENTAL
Intervention: Right superior PV (RSPV)
Number of subjects: 222
Study 35074890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (cilostazol with aspirin or clopidogrel) in the 15-28 days group
Number of subjects: 1879
Study 35074890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (cilostazol with aspirin or clopidogrel) in the 29-180 days group
Number of subjects: 1879
Study 35074890 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (aspirin or clopidogrel) in the 8-14 days group
Number of subjects: 1879
Study 35074890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (cilostazol with aspirin or clopidogrel)
Number of subjects: 1879
Study 35074890 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (aspirin or clopidogrel)
Number of subjects: 1879
Study 32406808 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid back
Number of subjects: 50
Study 32406808 — intervention group
Group type: COMPARATOR
Intervention: Upholstered back
Number of subjects: 50
Study 32862249 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia
Number of subjects: 40
Study 32862249 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized anesthesia (Calaject®)
Number of subjects: 40
Study 32862249 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for anesthesia technique
Number of subjects: 40
Study 35284929 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield during hand CT scan (MDCT)
Number of subjects: 0
Study 35284929 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield during hand CT scan (CBCT)
Number of subjects: 0
Study 35284929 — intervention group
Group type: COMPARATOR
Intervention: Non-shielded group
Number of subjects: 0
Study 33793713 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade A1 (single tumour 3 cm or smaller and anatomical R0 resection)
Number of subjects: 16931
Study 33793713 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade A2 (single tumour larger than 3 cm, or non-anatomical R0 resection)
Number of subjects: 16931
Study 33793713 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade B (multiple tumours, or vascular invasion, and R0 resection)
Number of subjects: 16931
Study 33793713 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade C (multiple tumours with vascular invasion and R0 resection, or R1 resection)
Number of subjects: 16931
Study 32717045 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily FDC antihypertensive pill (telmisartan, 20 mg; amlodipine, 2.5 mg; chlorthalidone, 12.5 mg)
Number of subjects: 700
Study 32717045 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study 33478495 — intervention group
Group type: EXPERIMENTAL
Intervention: START app
Number of subjects: 50
Study 33478495 — intervention group
Group type: EXPERIMENTAL
Intervention: START app features (entering daily step counts, reminders, motivational messages)
Number of subjects: 50
Study 33164553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3730
Study 35139832 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing training based on family-centered empowerment pattern
Number of subjects: 60
Study 35139832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 34580947 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of maternal risk factors, mean arterial pressure (MAP), serum placental growth factor (PlGF), and serum soluble fms-like tyrosine kinase-1 (sFLT-1) (triple test)
Number of subjects: 29677
Study 34580947 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple test (without UtA-PI)
Number of subjects: 29677
Study 34269974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium iron EDTA (NaFeEDTA) salt-enriched fish powder (250 mg/100 g)
Number of subjects: 123
Study 34269974 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 123
Study 34980184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (0.75 mg/kg, max 75 mg)
Number of subjects: 140
Study 34980184 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac (30 mg)
Number of subjects: 140
Study 32769754 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ophthalmology attending feedback
Number of subjects: 10
Study 32769754 — intervention group
Group type: COMPARATOR
Intervention: No remote feedback
Number of subjects: 10
Study 35195012 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 538
Study 35195012 — intervention group
Group type: COMPARATOR
Intervention: Delayed coronary angiography
Number of subjects: 538
Study 34139047 — intervention group
Group type: EXPERIMENTAL
Intervention: MM - mechanical debridement + metronidazole-minocycline ointment
Number of subjects: 114
Study 34139047 — intervention group
Group type: EXPERIMENTAL
Intervention: MC - mechanical debridement + minocycline ointment
Number of subjects: 114
Study 34139047 — intervention group
Group type: COMPARATOR
Intervention: NST - mechanical debridement only
Number of subjects: 114
Study 34139047 — intervention group
Group type: EXPERIMENTAL
Intervention: MM
Number of subjects: 114
Study 32444567 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid management for the first 72 hours
Number of subjects: 100
Study 32444567 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid management for the first 72 hours
Number of subjects: 100
Study 32444567 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid management
Number of subjects: 100
Study 36162865 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support program in Uganda and Sweden
Number of subjects: 0
Study 36162865 — intervention group
Group type: EXPERIMENTAL
Intervention: Care companion in South Africa
Number of subjects: 0
Study 36162865 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-facility link
Number of subjects: 0
Study 36162865 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous capacity building
Number of subjects: 0
Study 36162865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implementation process
Number of subjects: 0
Study 32522073 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing E. coli isolates
Number of subjects: 216
Study 32522073 — intervention group
Group type: EXPERIMENTAL
Intervention: PFGE types
Number of subjects: 216
Study 34353650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (5 mg/kg intramuscular injection)
Number of subjects: 80
Study 34353650 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and Haloperidol (5 mg midazolam and 5 mg haloperidol intramuscular injection)
Number of subjects: 80
Study 34353650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 80
Study 34353650 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and Haloperidol
Number of subjects: 80
Study 32334141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 33921381 — intervention group
Group type: EXPERIMENTAL
Intervention: Average ambient temperature between 0 and 10 °C
Number of subjects: 154
Study 33921381 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest statistical model
Number of subjects: 154
Study 33921381 — intervention group
Group type: EXPERIMENTAL
Intervention: Population age, temperature, and international tourism
Number of subjects: 154
Study 32158186 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg on a 4-week cycle)
Number of subjects: 32
Study 36163892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once-daily until disease progression or unacceptable toxicity (n=136)
Number of subjects: 269
Study 36163892 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil 0.5-0.8 mg/kg for ≤12 cycles (n=133)
Number of subjects: 269
Study 36163892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once-daily
Number of subjects: 269
Study 34212534 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC/histology-based classifier integrating NRP1, RGS5, FOXM1, and tumour necrosis
Number of subjects: 342
Study 34212534 — intervention group
Group type: COMPARATOR
Intervention: ClearCode34 classifier
Number of subjects: 342
Study 32283727 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention condition
Number of subjects: 66
Study 32283727 — intervention group
Group type: COMPARATOR
Intervention: Goal condition
Number of subjects: 66
Study 32283727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-over-body beliefs
Number of subjects: 66
Study 36247079 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 0.9% solution for nasopharyngeal wash
Number of subjects: 50
Study 36247079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 36247079 — intervention group
Group type: COMPARATOR
Intervention: Comparison between normal saline and control
Number of subjects: 50
Study 34152880 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Lawsonia inermis L. (Henna) hydrogel (H.gel) applied four times a day for 2 weeks
Number of subjects: 18
Study 34152880 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied four times a day for 2 weeks
Number of subjects: 18
Study 34753776 — intervention group
Group type: EXPERIMENTAL
Intervention: HE-MACS score
Number of subjects: 629
Study 34753776 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAR score
Number of subjects: 629
Study 32662827 — intervention group
Group type: COMPARATOR
Intervention: Mechanical brushing (MB; brush and dentifrice, control)
Number of subjects: 38
Study 32662827 — intervention group
Group type: EXPERIMENTAL
Intervention: MB with oral irrigation (Waterpik [WP], experimental)
Number of subjects: 38
Study 35853672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep First Group
Number of subjects: 40
Study 35853672 — intervention group
Group type: COMPARATOR
Intervention: Wake First Group
Number of subjects: 40
Study 34531216 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based programme, 1 hour per day for 6 days a week, for 24 weeks
Number of subjects: 250
Study 34531216 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 250
Study 34966120 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES) treatment, 4 sessions over 2 weeks
Number of subjects: 26
Study 34966120 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 32218302 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks TDM (The Daily Mile)
Number of subjects: 659
Study 32218302 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks TDM + additional personal support
Number of subjects: 659
Study 32218302 — intervention group
Group type: COMPARATOR
Intervention: Control (no TDM)
Number of subjects: 659
Study 35940873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intravenous paracetamol (10 mg/kg/dose 6 hourly for 72 hours)
Number of subjects: 102
Study 35940873 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose intravenous paracetamol (15 mg/kg/dose 6 hourly for 120 hours)
Number of subjects: 102
Study 35940873 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Low dose and Conventional dose)
Number of subjects: 102
Study 34351205 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent expert testimony
Number of subjects: 93
Study 34351205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adversarial expert testimony
Number of subjects: 93